IMV Inc. (IMV.TO)
| Previous Close | 0.9200 |
| Open | 0.9000 |
| Bid | 0.9200 x 0 |
| Ask | 0.9600 x 0 |
| Day's Range | 0.9000 - 0.9500 |
| 52 Week Range | 0.8400 - 3.0100 |
| Volume | |
| Avg. Volume | 42,000 |
| Market Cap | 78.156M |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6690 |
| Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.95 |
- Baystreet
Stocks in play: IMV Inc.
Announced the drawdown of the remaining $10 million U.S. available under its existing $25-million U.S. ...
- Business Wire
IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., June 22, 2022--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the drawdown of the remaining US$10 million available under its existing US$25 million debt facility led by Horizon Technology Finance Corporation (Nasdaq: HRZN) ("Horizon"). This drawdown has been made available as the Company achieved a pr
- Business Wire
IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 17, 2022--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in person at the H.C. Wainwright Global Investment Conference, which will be held in person and virtually May 23-26, 2022 in Miami, FL.
